Athira Pharma (NASDAQ:ATHA) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Athira Pharma (NASDAQ:ATHAGet Rating) announced its quarterly earnings results on Thursday. The company reported ($0.56) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.01), MarketWatch Earnings reports.

Shares of ATHA stock opened at $8.28 on Friday. Athira Pharma has a twelve month low of $7.56 and a twelve month high of $23.64. The company’s 50-day moving average price is $11.01 and its 200-day moving average price is $11.72.

In other news, Director Kelly A. Romano bought 8,000 shares of the firm’s stock in a transaction on Thursday, March 31st. The shares were bought at an average cost of $13.11 per share, for a total transaction of $104,880.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this hyperlink. 14.90% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the company. BlackRock Inc. increased its position in shares of Athira Pharma by 22.2% during the 4th quarter. BlackRock Inc. now owns 2,455,684 shares of the company’s stock worth $31,998,000 after purchasing an additional 446,781 shares during the last quarter. Wasatch Advisors Inc. raised its stake in shares of Athira Pharma by 2.6% in the 1st quarter. Wasatch Advisors Inc. now owns 1,274,791 shares of the company’s stock valued at $17,210,000 after acquiring an additional 32,368 shares during the period. State Street Corp lifted its holdings in shares of Athira Pharma by 22.7% in the 4th quarter. State Street Corp now owns 595,294 shares of the company’s stock worth $7,757,000 after acquiring an additional 110,041 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Athira Pharma by 45.0% during the 4th quarter. Geode Capital Management LLC now owns 559,500 shares of the company’s stock worth $7,290,000 after purchasing an additional 173,752 shares during the period. Finally, Morgan Stanley increased its holdings in Athira Pharma by 1,132.1% in the 2nd quarter. Morgan Stanley now owns 276,538 shares of the company’s stock valued at $2,831,000 after purchasing an additional 254,093 shares during the last quarter. 69.76% of the stock is currently owned by institutional investors and hedge funds.

A number of analysts have recently commented on ATHA shares. BTIG Research began coverage on Athira Pharma in a research report on Tuesday. They issued a “buy” rating and a $33.00 price objective for the company. Berenberg Bank initiated coverage on shares of Athira Pharma in a report on Thursday, April 21st. They set a “buy” rating and a $33.00 price objective on the stock. JMP Securities reissued a “buy” rating and set a $51.00 target price on shares of Athira Pharma in a research note on Friday, March 25th. Finally, Zacks Investment Research lowered shares of Athira Pharma from a “buy” rating to a “hold” rating in a research note on Friday, April 22nd. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $29.40.

Athira Pharma Company Profile (Get Rating)

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease.

Featured Articles

Earnings History for Athira Pharma (NASDAQ:ATHA)

Receive News & Ratings for Athira Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athira Pharma and related companies with MarketBeat.com's FREE daily email newsletter.